VIDEO ON HOW TO TAKE INSULIN
A very useful video on how to take INSULIN.
Source : https://youtu.be/Pl28IILPDTU
Friday 24 August 2018
Friday 30 March 2018
i-PORT INJECTION PORT
The i-port is an injection port that gives insulin injectors a means to give themselves their doses without having to puncture the skin for each dose. It might also be useful for parents of small children with diabetes.
In place for 3 days
Each i-port stays in place for up to three days and does not need to be removed for most daily activities (like taking a bath or shower).
Basically, once you’ve popped one in, you don’t have to do another one for a few days and you use the i-port as the injection site during that period.
Needless needles!
The advantage is that those fearful of needles can use the i-port to deliver insulin making each individual shot less of a drama (if you do think they are a drama). Use of the i-port should encourage better adherence to insulin regimes for those with needle phobia. When applying the i-port, an insertion needle guides a soft cannula (a small, flexible tube) under the skin.
Cannulas
Once applied, the insertion needle is removed and a soft cannula remains below the skin, acting as the gateway into the subcutaneous tissue. When injecting through the i-port, the needle of the syringe or insulin pen remains above the surface of the skin, while the medication is immediately delivered through the soft cannula and into the subcutaneous tissue.
The cannulas come in 6 mm and 9 mm lengths. Needles used with an i-port should not exceed 5/16” (8mm) in length. Each port should be able to handle up to 75 needle sticks over 72 hours (which would be very intensive insulin therapy indeed – you’re likely only to need to do 12-16 over a 3-day timeframe). Each i-port comes packaged individually in a box of 10 devices (roughly a month’s supply).
https://www.diabetes.co.uk/diabetic-products/iport-injection-port.html
The i-port is an injection port that gives insulin injectors a means to give themselves their doses without having to puncture the skin for each dose. It might also be useful for parents of small children with diabetes.
In place for 3 days
Each i-port stays in place for up to three days and does not need to be removed for most daily activities (like taking a bath or shower).
Basically, once you’ve popped one in, you don’t have to do another one for a few days and you use the i-port as the injection site during that period.
Needless needles!
The advantage is that those fearful of needles can use the i-port to deliver insulin making each individual shot less of a drama (if you do think they are a drama). Use of the i-port should encourage better adherence to insulin regimes for those with needle phobia. When applying the i-port, an insertion needle guides a soft cannula (a small, flexible tube) under the skin.
Cannulas
Once applied, the insertion needle is removed and a soft cannula remains below the skin, acting as the gateway into the subcutaneous tissue. When injecting through the i-port, the needle of the syringe or insulin pen remains above the surface of the skin, while the medication is immediately delivered through the soft cannula and into the subcutaneous tissue.
The cannulas come in 6 mm and 9 mm lengths. Needles used with an i-port should not exceed 5/16” (8mm) in length. Each port should be able to handle up to 75 needle sticks over 72 hours (which would be very intensive insulin therapy indeed – you’re likely only to need to do 12-16 over a 3-day timeframe). Each i-port comes packaged individually in a box of 10 devices (roughly a month’s supply).
https://www.diabetes.co.uk/diabetic-products/iport-injection-port.html
Wednesday 28 February 2018
Blood pressure drug could prevent 60 per cent of type 1 diabetes cases, say researchers
Blood pressure drug could prevent 60 per cent of type 1 diabetes
A drug normally associated with treating high blood pressure could help prevent type 1 diabetes in 60% of at-risk people, researchers have said.
Methyldopa has been around for more than 50 years and is often given to pregnant women and children with high blood pressure, but now it is believed it could have other uses.
Researchers say they have found evidence that it could be beneficial in the prevention of type 1 diabetes because the drug can block the DQ8 molecule, found in around 60% of people at high risk of developing type 1 diabetes.
Professor Aaron Michels, a researcher at the Barbara Davis Center for childhood diabetes and associate professor of medicine at the University of Colorado Anschutz Medical Campus, said: "With this drug, we can potentially prevent up to 60% of type 1 diabetes in those at risk for the disease. This is a very significant development."
The team spent 10 years studying the oral drug, normally taken between two and three times a day, and what effect it had on mice and 20 people with type 1 diabetes.
Prof Michels said: "We can now predict with almost 100 per cent accuracy who is likely to get type 1 diabetes. The goal with this drug is to delay or prevent the onset of the disease among those at risk."
Fellow researcher David Ostrov, PhD, hopes their methyldopa discovery might help block other molecules which could mean preventing other diseases.
Professor Ostrov, associate professor at the University of Florida College of Medicine's Center for NeuroGenetics, said: "This study has significant implications for treatment of diabetes and also other autoimmune diseases [and] suggests that the same approach may be adapted to prevent autoimmune diseases such as rheumatoid arthritis, coeliac disease, multiple sclerosis, systemic lupus erythematosus and others."
The findings of the study have been published in the Journal of Clinical Investigation
SOURCE : https://www.diabetes.co.uk/news/2018/feb/blood-pressure-drug-could-prevent-60-per-cent-of-type-1-diabetes-cases,-say-researchers-94241987.html
Wednesday 31 January 2018
Women who have gestational diabetes in pregnancy are at higher risk of future health issues
Women who have gestational diabetes mellitus (GDM) during pregnancy have a higher than usual risk of developing type 2 diabetes, hypertension, and ischemic heart disease in the future, according to new research led by the University of Birmingham.
The retrospective cohort study, a collaboration between the Universities of Birmingham, Auckland, and Warwick, as well as University Hospitals Birmingham NHS Foundation Trust, was published today in PLOS Medicine.
The researchers studied the incidence of type 2 diabetes, hypertension and ischemic heart and cerebrovascular diseases in a UK primary care database that included more than 9,000 women diagnosed with GDM between 1990 and 2016.
The study found that women diagnosed with GDM were over 20 times more likely to be diagnosed with type 2 diabetes later in life, over two and a half times more likely to develop ischemic heart disease and almost twice as likely to develop hypertension.
Dr Krish Nirantharakumar, of the University of Birmingham's Institute of Applied Health Research, said: "Results showed women diagnosed with GDM were significantly more likely to develop hypertension and ischemic heart disease at a relatively young age compared with women without a previous diagnosis of GDM in addition to the established risk of developing diabetes. The risk was greatest for type 2 diabetes in the first year following diagnosis of GDM and persisted throughout the follow-up period.
The findings add an important insight into the trajectory of the development of type 2 diabetes, hypertension and cardiovascular disease in the early and latter post-partum periods.
"Furthermore, the findings are the first to report on a large UK population and identify an at-risk group of relatively young women ideally suited for targeting risk factor management to improve long term metabolic and cardiovascular outcomes."
Although current guidelines recommend annual screening for diabetes in women diagnosed with GDM, the study also found that follow-up screening for diabetes as well as cardiovascular risk factors was low. With the exception of blood pressure, less than 60% of women were screened in the first year after giving birth and decreased to less than 40% by the second year after having their baby.
Barbara Daly, of the Faculty of Medical and Health Sciences at the University of Auckland, said the research was especially important given that the prevalence of GDM is increasing rapidly in most developed countries.
She added: "Guideline recommendations for screening and management of hypertension, lipids and smoking cessation are lacking and need to be reviewed.
"Although the NICE guidelines recommend annual screening for type 2 diabetes in women diagnosed with GDM, this study found follow-up screening was poor for type 2 diabetes and other cardiovascular risk factors such as hypertension.
"Clinical guidelines need to include post-partum screening and management for all cardiovascular risk factors in women diagnosed with GDM and not restrict it to diabetes."
SOURCE : https://www.sciencedaily.com/releases/2018/01/180116151450.htm
Women who have gestational diabetes mellitus (GDM) during pregnancy have a higher than usual risk of developing type 2 diabetes, hypertension, and ischemic heart disease in the future, according to new research led by the University of Birmingham.
The retrospective cohort study, a collaboration between the Universities of Birmingham, Auckland, and Warwick, as well as University Hospitals Birmingham NHS Foundation Trust, was published today in PLOS Medicine.
The researchers studied the incidence of type 2 diabetes, hypertension and ischemic heart and cerebrovascular diseases in a UK primary care database that included more than 9,000 women diagnosed with GDM between 1990 and 2016.
The study found that women diagnosed with GDM were over 20 times more likely to be diagnosed with type 2 diabetes later in life, over two and a half times more likely to develop ischemic heart disease and almost twice as likely to develop hypertension.
Dr Krish Nirantharakumar, of the University of Birmingham's Institute of Applied Health Research, said: "Results showed women diagnosed with GDM were significantly more likely to develop hypertension and ischemic heart disease at a relatively young age compared with women without a previous diagnosis of GDM in addition to the established risk of developing diabetes. The risk was greatest for type 2 diabetes in the first year following diagnosis of GDM and persisted throughout the follow-up period.
The findings add an important insight into the trajectory of the development of type 2 diabetes, hypertension and cardiovascular disease in the early and latter post-partum periods.
"Furthermore, the findings are the first to report on a large UK population and identify an at-risk group of relatively young women ideally suited for targeting risk factor management to improve long term metabolic and cardiovascular outcomes."
Although current guidelines recommend annual screening for diabetes in women diagnosed with GDM, the study also found that follow-up screening for diabetes as well as cardiovascular risk factors was low. With the exception of blood pressure, less than 60% of women were screened in the first year after giving birth and decreased to less than 40% by the second year after having their baby.
Barbara Daly, of the Faculty of Medical and Health Sciences at the University of Auckland, said the research was especially important given that the prevalence of GDM is increasing rapidly in most developed countries.
She added: "Guideline recommendations for screening and management of hypertension, lipids and smoking cessation are lacking and need to be reviewed.
"Although the NICE guidelines recommend annual screening for type 2 diabetes in women diagnosed with GDM, this study found follow-up screening was poor for type 2 diabetes and other cardiovascular risk factors such as hypertension.
"Clinical guidelines need to include post-partum screening and management for all cardiovascular risk factors in women diagnosed with GDM and not restrict it to diabetes."
SOURCE : https://www.sciencedaily.com/releases/2018/01/180116151450.htm
Subscribe to:
Posts (Atom)